Multi-valent pneumococcal conjugate vaccine for global health: From problem to platform to production
Childhood bacterial meningitis and pneumonia represent leading causes of mortality, with the latter persisting as one of the top causes of mortality for children under 5 y of age. The prohibitive costs of developing and producing broader spectrum conjugate vaccines impact availability and affordabil...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2022.2117949 |
| _version_ | 1797673143126458368 |
|---|---|
| author | Anup Datta Kapil Kapre Indah Andi-Lolo Subhash Kapre |
| author_facet | Anup Datta Kapil Kapre Indah Andi-Lolo Subhash Kapre |
| author_sort | Anup Datta |
| collection | DOAJ |
| description | Childhood bacterial meningitis and pneumonia represent leading causes of mortality, with the latter persisting as one of the top causes of mortality for children under 5 y of age. The prohibitive costs of developing and producing broader spectrum conjugate vaccines impact availability and affordability, resulting in a barrier to health equity and access to disease preventing vaccines, which restrict global health disease prevention efforts. Inventprise was founded in response to the need for innovation that can help reduce disease burden with improved coverage and more affordable vaccines. Inventprise 25-valent pneumococcal conjugate vaccine candidate with the patented Hz-PEG-Hz linker technology platform is expected to provide the broadest coverage against pathogenic pneumococcal serotypes encountered by populations regardless of where they live. The innovative automation technology and tightly controlled manufacturing requirements were implemented to mitigate the high capital cost for constructing a manufacturing facility in the United States, in addition to the prohibitive cost for the workforce required for running a complex plant. |
| first_indexed | 2024-03-11T21:41:10Z |
| format | Article |
| id | doaj.art-e47c9e2550e04508a5a47021262f8567 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:41:10Z |
| publishDate | 2022-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-e47c9e2550e04508a5a47021262f85672023-09-26T13:19:09ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-11-0118410.1080/21645515.2022.21179492117949Multi-valent pneumococcal conjugate vaccine for global health: From problem to platform to productionAnup Datta0Kapil Kapre1Indah Andi-Lolo2Subhash Kapre3Inventprise, IncInventprise, IncInventprise, IncInventprise, IncChildhood bacterial meningitis and pneumonia represent leading causes of mortality, with the latter persisting as one of the top causes of mortality for children under 5 y of age. The prohibitive costs of developing and producing broader spectrum conjugate vaccines impact availability and affordability, resulting in a barrier to health equity and access to disease preventing vaccines, which restrict global health disease prevention efforts. Inventprise was founded in response to the need for innovation that can help reduce disease burden with improved coverage and more affordable vaccines. Inventprise 25-valent pneumococcal conjugate vaccine candidate with the patented Hz-PEG-Hz linker technology platform is expected to provide the broadest coverage against pathogenic pneumococcal serotypes encountered by populations regardless of where they live. The innovative automation technology and tightly controlled manufacturing requirements were implemented to mitigate the high capital cost for constructing a manufacturing facility in the United States, in addition to the prohibitive cost for the workforce required for running a complex plant.http://dx.doi.org/10.1080/21645515.2022.2117949pneumococcuspneumococcal conjugate vaccinevaccine developmentgavigates foundationinventprise |
| spellingShingle | Anup Datta Kapil Kapre Indah Andi-Lolo Subhash Kapre Multi-valent pneumococcal conjugate vaccine for global health: From problem to platform to production Human Vaccines & Immunotherapeutics pneumococcus pneumococcal conjugate vaccine vaccine development gavi gates foundation inventprise |
| title | Multi-valent pneumococcal conjugate vaccine for global health: From problem to platform to production |
| title_full | Multi-valent pneumococcal conjugate vaccine for global health: From problem to platform to production |
| title_fullStr | Multi-valent pneumococcal conjugate vaccine for global health: From problem to platform to production |
| title_full_unstemmed | Multi-valent pneumococcal conjugate vaccine for global health: From problem to platform to production |
| title_short | Multi-valent pneumococcal conjugate vaccine for global health: From problem to platform to production |
| title_sort | multi valent pneumococcal conjugate vaccine for global health from problem to platform to production |
| topic | pneumococcus pneumococcal conjugate vaccine vaccine development gavi gates foundation inventprise |
| url | http://dx.doi.org/10.1080/21645515.2022.2117949 |
| work_keys_str_mv | AT anupdatta multivalentpneumococcalconjugatevaccineforglobalhealthfromproblemtoplatformtoproduction AT kapilkapre multivalentpneumococcalconjugatevaccineforglobalhealthfromproblemtoplatformtoproduction AT indahandilolo multivalentpneumococcalconjugatevaccineforglobalhealthfromproblemtoplatformtoproduction AT subhashkapre multivalentpneumococcalconjugatevaccineforglobalhealthfromproblemtoplatformtoproduction |